{"prompt": "['Abbreviated Title: Ph II SGI110 in Peds & Adults', '33', 'Version Date: 07/22/2019', 'according to the definitions stated below. (Note: Patients who exhibit objective disease', 'progression prior to the end of cycle 1 will also be considered evaluable.)', 'Evaluable Non-Target Disease Response: Patients who have lesions present at baseline that are', 'evaluable but do not meet the definitions of measurable disease, have received at least one cycle', 'of therapy, and have had their disease re-evaluated will be considered evaluable for non-target', 'disease. The response assessment is based on the presence, absence, or unequivocal progression', 'of the lesions.', '8.2 DISEASE PARAMETERS', 'Measurable disease: Measurable lesions are defined as those that can be accurately measured in', 'at least one dimension (longest diameter to be recorded) as >20 mm by chest x-ray, as >10 mm', 'with CT scan, or >10 mm with calipers by clinical exam. All tumor measurements must be', 'recorded in millimeters (or decimal fractions of centimeters).', 'Note: Tumor lesions that are situated in a previously irradiated area might or might not be', 'considered measurable. If the investigator thinks it appropriate to include them, the conditions', 'under which such lesions should be considered must be defined in the protocol.', 'Malignant lymph nodes. To be considered pathologically enlarged and measurable, a lymph', 'node must be >15 mm in short axis when assessed by CT scan (CT scan slice thickness', 'recommended to be no greater than 5 mm). Atbaseline and in follow-up, only the short axis will', 'be measured and followed.', 'Non-measurable disease. All other lesions (or sites of disease), including small lesions (longest', 'diameter <10 mm or pathological lymph nodes with >10 to <15 mm short axis), are considered', 'non-measurable disease. Bone lesions, leptomeningeal disease, ascites, pleural/pericardial', 'effusions, lymphangitis cutis/pulmonitis, inflammatory breast disease, and abdominal masses', '(not followed by CT or MRI), are considered as non-measurable.', 'Note: Cystic lesions that meet the criteria for radiographically defined simple cysts should not', 'be considered as malignant lesions (neither measurable nor non-measurable) since they are, by', 'definition, simple cysts.', \"'Cystic lesions' thought to represent cystic metastases can be considered as measurable lesions,\", 'if they meet the definition of measurability described above. However, if non-cystic lesions are', 'present in the same patient, these are preferred for selection as target lesions.', 'Target lesions. All measurable lesions up to a maximum of 2 lesions per organ and 5 lesions in', 'total, representative of all involved organs, should be identified as target lesions and recorded', 'and measured at baseline. Target lesions should be selected on the basis of their size (lesions', 'with the longest diameter), be representative of all involved organs, but in addition should be', 'those that lend themselves to reproducible repeated measurements. It may be the case that, on', 'occasion, the largest lesion does not lend itself to reproducible measurement in which', 'circumstance the next largest lesion which can be measured reproducibly should be selected. A', 'sum of the diameters (longest for non-nodal lesions, short axis for nodal lesions) for all target', 'lesions will be calculated and reported as the baseline sum diameters. If lymph nodes are to be', 'included in the sum, then only the short axis is added into the sum. The baseline sum diameters']['Abbreviated Title: Ph II SGI110 in Peds & Adults', '34', 'Version Date: 07/22/2019', 'will be used as reference to further characterize any objective tumor regression in the measurable', 'dimension of the disease.', 'Non-target lesions. All other lesions (or sites of disease) including any measurable lesions over', 'and above the 5 target lesions should be identified as non-target lesions and should also be', 'recorded at baseline. Measurements of these lesions are not required, but the presence, absence,', 'or in rare cases unequivocal progression of each should be noted throughout follow-up.', '8.2.1 Methods for Evaluation of Measurable Disease', 'All measurements should be taken and recorded in metric notation using a ruler or calipers. All', 'baseline evaluations should be performed as closely as possible to the beginning of treatment and', 'never more than 4 weeks before the beginning of the treatment.', 'The same method of assessment and the same technique should be used to characterize each', 'identified and reported lesion at baseline and during follow-up. Imaging-based evaluation is', 'preferred to evaluation by clinical examination unless the lesion(s) being followed cannot be', 'imaged but are assessable by clinical exam.', 'Clinical lesions: Clinical lesions will only be considered measurable when they are superficial', '(e.g., skin nodules and palpable lymph nodes) and >10 mm diameter as assessed using calipers', '(e.g., skin nodules). In the case of skin lesions, documentation by color photography, including a', 'ruler to estimate the size of the lesion, is recommended.', 'Chest x-ray: Lesions on chest x-ray are acceptable as measurable lesions when they are clearly', 'defined and surrounded by aerated lung. However, CT is preferable.', 'Conventional CT and MRI: This guideline has defined measurability of lesions on CT scan', 'based on the assumption that CT slice thickness is 5 mm or less. If CT scans have slice thickness', 'greater than 5 mm, the minimum size for a measurable lesion should be twice the slice thickness.', 'MRI is also acceptable in certain situations (e.g. for body scans).', 'Use of MRI remains a complex issue. MRI has excellent contrast, spatial, and temporal', 'resolution; however, there are many image acquisition variables involved in MRI, which greatly', 'impact image quality, lesion conspicuity, and measurement. Furthermore, the availability of', 'MRI is variable globally. As with CT, if an MRI is performed, the technical specifications of the', 'scanning sequences used should be optimized for the evaluation of the type and site of disease.', 'Furthermore, as with CT, the modality used at follow-up should be the same as was used at', 'baseline and the lesions should be measured/assessed on the same pulse sequence. It is beyond', 'the scope of the RECIST guidelines to prescribe specific MRI pulse sequence parameters for all', 'scanners, body parts, and diseases. Ideally, the same type of scanner should be used and the', 'image acquisition protocol should be followed as closely as possible to prior scans. Body scans', 'should be performed with breath-hold scanning techniques, if possible.', 'PET-CT: At present, the low dose or attenuation correction CT portion of a combined PET-CT', 'is not always of optimal diagnostic CT quality for use with RECIST measurements. However, if', 'the site can document that the CT performed as part of a PET-CT is of identical diagnostic', 'quality to a diagnostic CT (with IV and oral contrast), then the CT portion of the PET-CT can be', 'used for RECIST measurements and can be used interchangeably with conventional', 'CT', 'in', 'accurately measuring cancer lesions over time. Note, however, that the PET portion of the CT']\n\n###\n\n", "completion": "END"}